Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of HBV variants and novel viral and immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated steatotic liver disease.

Journal of viral hepatitis - 1 Oct 2024

Patel Nishi H, Lucko Aaron, Vachon Alicia, Doucette Karen E, Ramji Alnoor, Sycuro Laura, Patel Trushar R, Chadee Kris, Raman Maitreyi, van Marle Guido, Osiowy Carla, Coffin Carla S

Abstract excerpt

Co-existing chronic hepatitis B virus (CHB) infection and metabolic dysfunction associated steatotic liver disease (MASLD) can exert complex effects on hepatic metabolism, requiring mechanistic study. CHB participants were assessed for MASLD and the impact of hepatic steatosis/metabolic syndrome (MetS) on novel viral and immunological markers. In this prospective, cohort study, untreated CHB subjects were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme-Linked Immunospot Assay
Share to Fatty Liver

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B Core Antigens

Share to Hepatitis B Surface Antigens

Share to Hepatitis B virus

Share to Metabolic Syndrome

Share to Viral Load

Source

Identifiers

PMID: 39109700
DOI: 10.1111/jvh.13979

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of HBV variants and novel viral and immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated steatotic liver disease.PMID 39109700Read ↗

Host and HBV Interactions and Their Potential Impact on Clinical OutcomeSemantic proximity Read ↗

PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLFSemantic proximity Read ↗

Host and HBV Interactions and Their Potential Impact on Clinical Outcomes.Semantic proximity Read ↗

A broad investigation of the HBV-mediated changes to primary hepatocyte physiology reveals HBV significantly alters metabolic pathwaysSemantic proximity Read ↗

The novel mechanism facilitating chronic hepatitis B infection: immunometabolism and epigenetic modification reprogrammingSemantic proximity Read ↗

Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B.Semantic proximity Read ↗

Persistent steatosis retards fibrosis regression during anti-HBV treatment in patients with chronic HBV infectionSemantic proximity Read ↗

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.Semantic proximity Read ↗

Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination.Semantic proximity Read ↗

New perspectives of biomarkers for the management of chronic hepatitis B.Semantic proximity Read ↗

Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseasesSemantic proximity Read ↗

Determination of hepatitis B phenotype using biochemical and serological markers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.